Transgene TG4010 Exclusive Option
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Later from Prescient Therapeutics
- December 2015 Appendix 4C - Quarterly
- Steven Yatomi-Clarke Appointed CEO
- PTX-200 Breast Cancer Trial Progresses
- Approval received to transfer IND Sponsorship for PTX-200
- December 2014 Appendix 4C - quarterly
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics